Teva Women’s Health, Inc. Announces New Data on Phase III Investigational Progesterone Vaginal Ring at the 68th Annual Meeting

  Teva Women’s Health, Inc. Announces New Data on Phase III Investigational
  Progesterone Vaginal Ring at the 68th Annual Meeting of the American Society
  for Reproductive Medicine

 - Data Demonstrates Efficacy of the Vaginal Progesterone Ring, Milprosa™, is
 Similar to Progesterone Gel and May Offer a Convenient Administration Route
                                 for Women -

Business Wire

FRAZER, Pa. -- October 23, 2012

Teva Women’s Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical
Industries Ltd. (NYSE: TEVA), today announced findings from a Phase III
clinical trial of Milprosa^TM (progesterone), an investigational weekly
progesterone vaginal ring for luteal supplementation in women undergoing in
vitro fertilization (IVF). These data were presented as an oral presentation
at the 68^th Annual Meeting of the American Society for Reproductive Medicine

Data from a randomized, single-blind trial assessing the pregnancy rate of
Milprosa™ versus daily 8 percent progesterone gel for luteal supplementation
in women undergoing embryo transfer during IVF at days three and five were
presented. Results showed clinical pregnancy rates for Milprosa™ were similar
to progesterone gel, regardless of the day the embryos were returned to the
uterus. Researchers concluded that Milprosa™ is effective in luteal
supplementation in IVF and that clinical pregnancy rates were similar for the
vaginal ring and 8 percent progesterone gel.^1

“We are encouraged by the data presented on Milprosa™ at ASRM this year, which
demonstrated that the vaginal progesterone ring may provide an appropriate
option for luteal phase support in IVF,” said Mark Perloe, MD, medical
director at Georgia Reproductive Specialists. “We look forward to having a new
once-weekly option available for patients going through IVF.^i

Additionally, results from a patient satisfaction survey, which were part of
the Phase III clinical trial, were also presented in a poster at ASRM. The
survey assessed all 1,297 women in the trial, who used either Milprosa™ or
progesterone gel. Of these women, 262 had used at least one progesterone
treatment in a previous IVF cycle prior to entering the Phase III study. Prior
progesterone treatments used included injection, oral/vaginal capsule, gel or
another method. When comparing their randomized treatment to former methods,
women randomized to Milprosa™ more frequently reported their randomized
treatment as a method that was more convenient, less messy, less stressful and
causing less leakage.^2

“We are pleased to have promising data on Milprosa™ presented at ASRM that
builds upon our heritage in women’s reproductive health products,” said Nancy
Ricciotti, senior director of clinical affairs, Teva Women’s Health R&D. “IVF
represents a new area of specialization for Teva and one in which significant
unmet needs exist. We hope to use our legacy in women’s health to help women
dealing with infertility achieve their reproductive goals.”

About Milprosa™

Teva’s investigational once-weekly progesterone vaginal ring, Milprosa™, is a
flexible transvaginal ring that is designed to continuously release a steady
dose of progesterone and is in development for luteal phase support for women
undergoing in-vitro fertilization.

About Teva Women’s Health, Inc.

Teva Women’s Health, Inc. is a U.S.-based subsidiary of Teva Pharmaceutical
Industries Ltd. (NYSE: TEVA), headquartered in Israel. The company produces a
wide range of women’s healthcare products including oral contraceptives,
intrauterine contraception and hormone therapy treatments for menopause and
perimenopause. Teva Women’s Health, Inc. maintains a strong commitment to
enhancing women’s lives by actively pursuing new areas of research and
providing distinct pharmaceutical options that meet women’s needs and fit
their lifestyles. Through close engagement with women and healthcare
providers, the company maintains an in-depth understanding of the important
health matters that affect women.

Teva’s Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995: The following discussion and analysis contains
forward-looking statements, which express the current beliefs and expectations
of management. Such statements involve a number of known and unknown risks and
uncertainties that could cause our future results, performance or achievements
to differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Important factors
that could cause or contribute to such differences include risks relating to:
our ability to develop and commercialize additional pharmaceutical products,
competition from the introduction of competing generic equivalents and due to
increased governmental pricing pressures, the effects of competition on sales
of our innovative medicines, especially Copaxone® (including competition from
innovative orally-administered alternatives as well as from potential generic
equivalents), potential liability for sales of generic medicines prior to a
final resolution of outstanding patent litigation, including that relating to
our generic version of Protonix®, the extent to which we may obtain U.S.
market exclusivity for certain of our new generic medicines, the extent to
which any manufacturing or quality control problems damage our reputation for
high quality production and require costly remediation, our ability to
identify, consummate and successfully integrate acquisitions (including the
acquisition of Cephalon), our ability to achieve expected results through our
innovative R&D efforts, dependence on the effectiveness of our patents and
other protections for innovative medicines, intense competition in our
specialty pharmaceutical businesses, uncertainties surrounding the legislative
and regulatory pathway for the registration and approval of
biotechnology-based medicines, our potential exposure to product liability
claims to the extent not covered by insurance, any failures to comply with the
complex Medicare and Medicaid reporting and payment obligations, our exposure
to currency fluctuations and restrictions as well as credit risks, the effects
of reforms in healthcare regulation and pharmaceutical pricing and
reimbursement, adverse effects of political instability and adverse economic
conditions, major hostilities or acts of terrorism on our significant
worldwide operations, increased government scrutiny in both the U.S. and
Europe of our agreements with brand companies, interruptions in our supply
chain or problems with our information technology systems that adversely
affect our complex manufacturing processes, the impact of continuing
consolidation of our distributors and customers, the difficulty of complying
with U.S. Food and Drug Administration, European Medicines Agency and other
regulatory authority requirements, potentially significant impairments of
intangible assets and goodwill, potential increases in tax liabilities
resulting from challenges to our intercompany arrangements, the termination or
expiration of governmental programs or tax benefits, any failure to retain key
personnel or to attract additional executive and managerial talent,
environmental risks, and other factors that are discussed in our Annual Report
on Form 20-F for the year ended December 31, 2011, in this report and in our
other filings with the U.S. Securities and Exchange Commission (“SEC”).
Forward-looking statements speak only as of the date on which they are made,
and we undertake no obligation to update any forward-looking statements or
other information contained in this report, whether as a result of new
information, future events or otherwise. You are advised, however, to consult
any additional disclosures we make in our reports to the SEC on Form 6-K. Also
note that we provide a cautionary discussion of risks and uncertainties under
“Risk Factors” in our Annual Report on Form 20-F for the year ended December
31, 2011. These are factors that we believe could cause our actual results to
differ materially from expected results. Other factors besides those listed
could also adversely affect us. This discussion is provided as permitted by
the Private Securities Litigation Reform Act of 1995.


^1 Perloe M, et al. Impact of Luteal Supplementation With a Weekly
Progesterone Vaginal Ring During In Vitro Fertilization (IVF) by Day of Embryo
Transfer (ET). Presented at 68th Annual Meeting of the American Society for
Reproductive Medicine. October 2012; San Diego, Calif. US.

^2 Silverberg K, et al. Satisfaction With Progesterone Vaginal Ring (PGN VR):
Survey of Women Participating in a Randomized Trial of Weekly PGN VR vs 8% PGN
Gel as Luteal Support After In Vitro Fertilization (IVF). Presented at 68th
Annual Meeting of the American Society for Reproductive Medicine. October
2012; San Diego, Calif. US.


Teva USA
Denise Bradley, 215-591-8974
Press spacebar to pause and continue. Press esc to stop.